Zirr AI – integrated with Clinical Decision Support System (CDSS) AI – transforms clinical documentation and patient care. Pulse 2.0 interviewed Zirr AI co-founder and CEO Arnavaz Hajizadeh to learn more about the company.
Arnavaz Hajizadeh’s Background
Screenshot
What is Arnavaz Hajizadeh’s background? Hajizadeh said:
“I am Arnavaz Hajizadeh, MD, PharmD, and I come from a medical background with experience in both clinical practice and pharmacy. My passion for improving healthcare processes led me to co-found Zirr AI Medical Scribe.”
Formation Of Zirr AI
How did the idea for the company come together? Hajizadeh shared:
“The idea for Zirr AI emerged from our firsthand experience with the challenges of clinical documentation. My co-founder, Ali Daneshmand, MD, and I realized that healthcare providers spend too much time on paperwork, which detracts from patient care. Our goal is to streamline this process through AI-driven solutions. My primary responsibilities include overseeing product development, strategic planning, and ensuring our technology meets the needs of our users.”
Favorite Memory
What has been your favorite memory working for the company so far? Hajizadeh reflected:
“One of my favorite memories has been receiving positive feedback from clinicians who have used our platform to significantly reduce their documentation burden. Seeing their relief and appreciation is incredibly rewarding.”
Core Products
What are the company’s core products and features? Hajizadeh explained:
“Zirr AI Medical Scribe focuses on providing ambient AI medical scribing services. Our core features include a real-time transcript, SOAP notes maker, and clinical decision support system. This allows clinicians to focus more on patient care and less on administrative tasks.”
Challenges Faced
What challenges have Hajizadeh and the team faced in building the company? Hajizadeh acknowledged:
“Recently, we faced challenges related to integrating our technology into diverse clinical workflows. We overcame this by engaging directly with our users to understand their needs better and iterating on our product based on their feedback.”
Evolution Of Zirr AI’s Technology
How has the company’s technology evolved since launching? Hajizadeh noted:
“Since our launch in April 2024, we have continuously improved our AI algorithms and user interface, incorporating user feedback to enhance the overall experience.”
Significant Milestones
What have been some of the company’s most significant milestones? Hajizadeh cited:
“Some key milestones include reaching hundreds of clinicians across the U.S. using our platform. We’re proud of our growth and the impact we’ve made in such a short time.”
Customer Success Stories
When asking Hajizadeh about customer success stories, she highlighted:
“One success story involves a nurse practitioner who reported a 50% reduction in time spent on documentation after implementing our solution, allowing her to see more patients and improve care quality.”
Funding
When asking Hajizadeh about the company’s funding details, she revealed:
“We are currently self-funded, but this might change soon.”
Total Addressable Market
What total addressable market (TAM) size is the company pursuing? Hajizadeh assessed:
“Estimates suggest that the total addressable market for our company exceeds $3.2 billion, driven by the increasing demand for AI solutions in healthcare, particularly within the medical scribing sector.”
Differentiation From The Competition
What differentiates the company from its competition? Hajizadeh affirmed:
“What sets us apart from our competition is our focus on ambient AI technology and the incorporation of Clinical Decision Support Systems (CDSS), which seamlessly integrate into clinicians’ workflows without disrupting patient interactions. Our strong medical background also informs our product development, ensuring that our solutions effectively meet the needs of healthcare providers and enhance patient care.”
Future Company Goals
What are some of the future company goals? Hajizadeh concluded:
“Looking ahead, we aim to expand our features, increase our market presence, and continue enhancing our technology to support various medical specialties.”
